1. Introduction
===============

Enterococci are commensal bacteria inhabiting the intestines of both humans and animals, which are the major conditionally pathogenic bacteria that cause hospital-acquired infections \[[@B1-ijerph-11-03424]\]. Recently, frequent inappropriate use of antimicrobial agents, increase in invasive therapy, and wide use of immunosuppressants has resulted in a growing rise in the number of clinical infections caused by *Enterococcus* spp., notably *Enterococcus faecium* \[[@B2-ijerph-11-03424]\]. In addition, the emergence of high-level aminoglycoside-resistant (HLAR) enterococci and vancomycin-resistant enterococci (VRE) causes great difficulties in clinical anti-infective therapy \[[@B3-ijerph-11-03424],[@B4-ijerph-11-03424],[@B5-ijerph-11-03424]\]. In this hospital-based study, a total of 1,157 *Enterococcus* strains isolated from a university hospital during the period from January 2010 through December 2012 were detected and identified to investigate the prevalence and antimicrobial resistance of *Enterococcus* species. In addition the mechanisms underlying the antimicrobial resistance were explored so as to provide clinical evidence for the inappropriate clinical use of antimicrobial agents and the control and prevention of enterococcal infections.

2. Materials and Methods
========================

2.1. Enterococcus Strains
-------------------------

A total of 1,157 enterococcal strains were isolated from 1,157 diverse clinical specimens obtained from January 2010 to December 2012 at the General Hospital of Ningxia Medical University (Yinchuan, China). All strains were identified to the species level with a VITEK-2 COMPACT fully automated microbiological system (bioMérieux, Inc.; Durham, NC, USA). The quality control strain *Enterococcus faecalis* ATCC 29212 was purchased from Shanghai Harmony Biotechnology Co., Ltd. (Shanghai, China).

2.2. Antibiotic Susceptibility Testing
--------------------------------------

The susceptibility of *Enterococcus* species to 16 antibiotics was determined using the Clinical Laboratory Standard Institute (CLSI) recommended, WHO modified Kirby-Bauer disc diffusion method \[[@B6-ijerph-11-03424]\].

2.3. Screening of Multiple-drug Resistant Enterococcal Isolates
---------------------------------------------------------------

A total of 100 multiple-drug resistant enterococcal isolates (resistant to at least three antibiotics) were screened from the 182 isolates of *Enterococcus* species from the burns department during the period between January 2010 and December 2012, and the antimicrobial resistance in these 100 multiple-drug resistant enterococcal strains is described in [Figure 1](#ijerph-11-03424-f001){ref-type="fig"} and [Table 1](#ijerph-11-03424-t001){ref-type="table"}.

![Antimicrobial resistance in 100 multiple-drug resistant enterococcal isolates.](ijerph-11-03424-g001){#ijerph-11-03424-f001}

### 2.3.1. Efflux Pump Inhibition Assay

The minimal inhibitory concentration (MIC) of *Enterococcus* species to the three fluoroquinolones, including ciprofloxacin, gatifloxacin and levofloxacin (Dalian Meilun Biology Technology Co., Ltd.; Dalian, China) at final concentrations of 0.25--512 mg/L, was determined with the agar dilution method \[[@B7-ijerph-11-03424]\], while *E. faecalis* ATCC 29212 served as a control isolate. In addition, the MIC of *Enterococcus* species to ciprofloxacin, gatifloxacin and levofloxacin following treatment with an efflux pump inhibitor reserpine (Dalian Meilun Biology Technology Co., Ltd.; (Dalian, China) at a concentration of 20 mg/L, while the antibiotics-free Mueller-Hinton (M-H) agar (Oxoid, Basingstoke, UK) medium containing 20 mg/L reserpine served as controls.
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###### 

Antimicrobial resistance in 100 isolates of *E. faecium* and *E. faecalis*.

  Antibiotics                 *E. faecium* (*n* = 62)   *E. faecalis* (*n* = 38)        
  --------------------------- ------------------------- -------------------------- ---- ------
  Penicillin                  55                        88.7                       2    5.3
  Ampicillin                  51                        82.3                       2    5.3
  High-level gentamicin       1                         1.6                        1    2.6
  Rifampicin                  49                        79.0                       17   44.7
  Ciprofloxacin               36                        58.1                       6    15.8
  Levofloxacin                28                        45.2                       5    13.2
  Fosfomycin                  15                        24.2                       3    7.9
  Erythromycin                56                        90.3                       20   52.6
  Furadantin                  7                         11.3                       1    2.6
  Linezolid                   0                         0.0                        0    0.0
  Vancomycin                  0                         0.0                        0    0.0
  Teicoplanin                 0                         0.0                        0    0.0
  Chloramphenicol             3                         4.8                        10   26.3
  Quinupristin/dalfopristin   0                         0.0                        25   65.8
  Minocycline                 20                        32.3                       18   47.4
  Tetracycline                30                        48.4                       26   68.4

### 2.3.2. Detection of Antimicrobial Resistance Genes

The 100 multiple-drug resistant enterococcal strains were isolated in pure cultures. Then, 6--8 enterococcal colonies were randomly selected, diluted with 200 µL of ddH~2~O, centrifuged, boiled at 95 °C for 10 min, followed by centrifugation at 12,000 r/min for 5 min, and the supernatant was the DNA of the enterococcal strains. The β-lactam, aminoglycoside, tetracycline, macrolide, glycopeptide resistance genes and the efflux pump genes were detected in the 100 multiple-drug resistant enterococcal isolates using a polymerase chain reaction (PCR) assay with primers ([Table 2](#ijerph-11-03424-t002){ref-type="table"}) synthesized by the Sangon Biotech (Shanghai) Co., Ltd. (Shanghai, China). PCR was performed with a 25 μL system containing 12.5 μL Premix Taq (BioTeke Biotech Co., Ltd.; Beijing, China), 1 μL DNA template, 1 μL of the forward and reverse primers, and 9.5 μL ddH~2~O under the following conditions: pre-degeneration at 94 °C for 3 min (at 93 °C for 2 min for the *ant(6)-I* and *tetM* genes and at 94 °C for 5 min for the *emeA* gene), followed by 35 cycles of degeneration at 94 °C for 40 s, annealing at 55 °C for 40 s, and extension at 72 °C for 40 s (35 cycles of degeneration at 93 °C for 30 s, annealing at 55 °C for 30 s, and extension at 72 °C for 60 s for the *ant(6)-I* gene; 35 cycles of degeneration at 93 °C for 60 s, annealing at 55 °C for 60 s, and extension at 72 °C for 60 s for the *tetM* gene; 30 cycles of degeneration at 94 °C for 45 s, annealing at 57 °C for 60 s, and extension at 72 °C for 90 s for the *emeA* gene), and final extension at 72 °C for 2 min (for 5 min for the *ant(6)-I* and *tetM* genes and for 10 min for the *emeA* gene). The amplification products were electrophoresed on 1.5% agarose gels (TAKARA Biotechnology (Dalian) Co., Ltd.; Dalian, China). Following electrophoresis, the agarose gels were stained with ethidium bromide for 15 min, and then visualized with a gel imaging analysis system with Quantity One software (Bio Rad; Hercules, CA, USA).
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###### 

Sequences of the primers for amplification of antibiotics-resistant genes in *Enterococcus* spp.

  Antibiotic-resistant *Enterococcus* spp.       Representative Gene          Sequence (5\'-3\')         Amplification Product Size (bp)
  ---------------------------------------------- ---------------------------- -------------------------- ---------------------------------
  β-lactam-resistant *Enterococcus* spp.         *TEM*                        P1:AGGAAGAGTATGATTCAACA    535
  P2:CTCGTCGTTTGGTATGGC                                                                                  
  Aminoglycoside-resistant *Enterococcus* spp.   *aac(6\')/aph(2\')*          P1:CCAAGAGCAATAAGGGCATA    220
  P2:CACTATCATAACCACTACCG                                                                                
  *aph(3\')-II*                                  P1:GCCGATGTGGATTGCGAAAA      292                        
  P2:GCTTGATCCCCAGTAAGTCA                                                                                
  *ant(6)-I*                                     P1:ACTGGCTTAATCAATTTGGG      597                        
  P2:GCCTTTCCGCCACCTCACC                                                                                 
  *ant(2\'\')-I*                                 P1:GAGCGAAATCTGCCGCTCTGG     320                        
  P2:CTGTTACAACGGACTGGCCGC                                                                               
  *ant(4\', 4")*                                 P1:GCAAGGACCGACAACATTTC      165                        
  P2:TGGCACAGATGGTCATAACC                                                                                
  Tetracycline-resistant *Enterococcus* spp.     *tetM*                       P1:GTGTGACGAACTTTACCGAA    501
  P2:GCTTTGTATCTCCAAGAACAC                                                                               
  Macrolide-resistant *Enterococcus* spp.        *ermB*                       P1:GAAAAGGTACTAAACCAAATA   616
  P2:AGTAACGGTACTTAAATTGTTTAC                                                                            
  *mefA*                                         P1:ACTATCATTAATCACTAGTGC     346                        
  P2:TTCTTCTGGTACTAAAAGTGG                                                                               
  Glycopeptide-resistant *Enterococcus* spp.     *vanA*                       P1: GGGAAAACGACAATTGC      732
  P2:GTACAATGCGGCCGTTA                                                                                   
  *vanB*                                         P1:CATCGCCGTCCCCGAATTTCAAA   297                        
  P2:GATGCGGAAGATACCGTGGCT                                                                               
  *vanC1*                                        P1:GGTATCAAGGAAACCTC         822                        
  P2:CTTCCGCCATCATAGCT                                                                                   
  *vanC2/3*                                      P1:CTCCTACGATTCTCTTG         439                        
  P2:CGAGCAAGACCTTTAAG                                                                                   
  Multidrug resistance efflux pump               *emeA*                       P1:GTGACAGCCTTTGTGGCAGAT   687
  P2:TAGTCCGTTGATGGTTCCTTG                                                                               

2.4. Statistical Analysis
-------------------------

All data were managed using the software WHONET version 5.6, and all statistical analyses were performed with the statistical software SPSS version 17.0 (SPSS Inc.; Chicago, IL, USA). The difference of antimicrobial sensitivity in *Enterococcus* species was compared with chi-square test, with a *p*-value \< 0.05 indicative of statistical significance.

3. Results
==========

3.1. Distribution of Enterococcus Species in Various Clinical Specimens
-----------------------------------------------------------------------

The 1,157 *Enterococcus* species were isolated from 1,157 clinical specimens collected between January 2010 to December 2012 in the hospital, including 679 *E. faecium* isolates (58.7%, 679/1,157), 382 *E. faecalis* isolates (33%, 382/1,157), 26 *E. casseliflavus* isolates (2.2%, 26/1,157), 24 *E. avium* isolates (2.1%, 24/1,157), and 46 isolates of other *Enterococcus* species (4%, 46/1,157). The MIC~50~ and MIC~90~ values of the 16 antibiotics against the four major enterococcal strains are shown in [Table 3](#ijerph-11-03424-t003){ref-type="table"}. The top five departments from which *Enterococcus* species were isolated ([Table 4](#ijerph-11-03424-t004){ref-type="table"}) included the burns department (15.7%), intensive care unit (ICU; 14.4%), pediatrics department (13.5%), urology department (5.8%) and respiratory medicine department (4.1%), and the highest prevalence of *Enterococcus* species was detected in urine specimens (31.4%), followed by pus specimens (24.4%) and secretion specimens (16%).

3.2. Sensitivity of Enterococcus Species to Antibiotics
-------------------------------------------------------

Of the 1,157 *Enterococcus* isolates, a low prevalence of resistance to linezolid, vancomycin and teicoplanin was detected, while over 40% prevalence of resistance to most antibiotics tested in this study was found. The prevalence of antimicrobial resistance in isolates of *E. faecium*, *E. faecalis*, *E. casseliflavus* and *E. avium* is presented in [Table 5](#ijerph-11-03424-t005){ref-type="table"}.

3.3. Comparison of Antimicrobial Resistance between E. faecium and E. faecalis
------------------------------------------------------------------------------

*E. faecium* and *E. faecalis* comprised 91.7% of the 1,157 *Enterococcus* species isolates collected from the hospital from January 2010 to December 2012. A significantly higher prevalence of resistance to penicillin, ampicillin, rifampicin, ciprofloxacin, levofloxacin, fosfomycin, erythromycin and furadantin was detected in *E. faecium* than that in *E. faecalis* (*p* \< 0.05), while a greater prevalence of resistance to chloramphenicol, quinupristin/dalfopristin, minocycline and tetracycline was found in *E. faecalis* than that in *E. faecium* (*p* \< 0.05). In addition, a low prevalence of resistance to linezolid, vancomycin and teicoplanin was detected in both *E. faecium* and *E. faecalis*.

3.4. Antimicrobial Resistance in Enterococcus Species Isolated from Various Departments of the Hospital
-------------------------------------------------------------------------------------------------------

The prevalence of antimicrobial resistance varied in the *Enterococcus* species isolated from different departments of the hospital. A lower prevalence was detected in the *Enterococcus* species isolated from the department of pediatrics, where a high prevalence of penicillin resistance was found, while the highest prevalence was found in the burns department ([Table 6](#ijerph-11-03424-t006){ref-type="table"}).
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###### 

MIC~50~ and MIC~90~ scales of 16 antibiotics against *Enterococcus* species (µg/mL).

  Antibiotics                 *E. faecium* (*n* = 679)   *E. faecalis* (*n* = 382)   *E. casseliflavus* (*n* = 26)   *E. avium* (*n* = 24)                     
  --------------------------- -------------------------- --------------------------- ------------------------------- ----------------------- ----- ----- ----- -----
  Penicillin                  64                         64                          2                               8                       0.5   2     1     64
  Ampicillin                  32                         32                          2                               16                      2     2     2     16
  High-level gentamicin \*    \-                         \-                          \-                              \-                      \-    \-    \-    \-
  Rifampicin                  16                         16                          8                               32                      1     2     2     2
  Ciprofloxacin               64                         128                         1                               16                      0.5   2     0.5   1
  Levofloxacin                8                          128                         1                               8                       2     4     1     2
  Fosfomycin                  64                         128                         32                              64                      64    256   32    32
  Erythromycin                64                         256                         16                              256                     1     8     8     8
  Furadantin                  64                         256                         16                              16                      16    32    32    128
  Linezolid                   2                          2                           2                               2                       2     4     1     2
  Vancomycin                  1                          1                           1                               2                       2     4     0.5   1
  Teicoplanin                 2                          4                           2                               2                       4     8     2     2
  Chloramphenicol             8                          16                          8                               32                      2     4     2     4
  Quinupristin/dalfopristin   0.5                        1                           4                               8                       1     2     2     4
  Minocycline                 8                          32                          16                              64                      2     8     4     8
  Tetracycline                8                          16                          16                              16                      1     16    16    16

Note: **\*** Only resistance found was against high-level gentamicin.
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###### 

Distribution of 1157 *Enterococcus* species isolated from various clinical departments.

  Clinical department                    *E. faecium* (*n* = 679)   *E. faecalis* (*n* = 382)   *E. casseliflavus* (*n* = 26)   *E. avium (n* = 24)   *E. raffinosus* (*n* = 18)   *E. gallinarum* (*n* = 7)   Other *Enterococcus* species (*n* = 21)
  -------------------------------------- -------------------------- --------------------------- ------------------------------- --------------------- ---------------------------- --------------------------- -----------------------------------------
  Department of burns                    73                         93                          7                               2                     2                            2                           3
  ICU                                    116                        37                          4                               3                     1                            1                           5
  Department of pediatrics               99                         44                          5                               1                     3                            2                           2
  Department of urology                  27                         38                          0                               1                     1                            0                           0
  Department of respiratory medicine     42                         5                           1                               0                     0                            0                           0
  Department of: hepatobiliary surgery   30                         8                           5                               0                     3                            0                           1
  Department of orthopedics              16                         18                          1                               2                     0                            1                           3
  Department of endocrinology            8                          9                           0                               1                     1                            0                           1
  Department of neurology                13                         4                           1                               0                     0                            0                           0
  Department of gynecology               6                          8                           0                               0                     2                            0                           0
  Other department                       249                        118                         2                               14                    5                            1                           6
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###### 

Antimicrobial resistance in *Enterococcus* species.

  Antibiotics                 *E. faecium* (*n* = 679)   *E. faecalis* (*n* = 382)   *E. casseliflavus* (*n* = 26)   *E. avium* (*n* = 24)                   
  --------------------------- -------------------------- --------------------------- ------------------------------- ----------------------- --- ------ ---- ------
  Penicillin                  621                        91.4                        22                              5.8                     1   3.8    8    33.3
  Ampicillin                  610                        89.8                        9                               2.4                     0   0.0    6    25.0
  High-level gentamicin       22                         3.2                         8                               2.1                     0   0.0    1    4.5
  Rifampicin                  566                        83.3                        191                             50.0                    0   0.0    0    0.0
  Ciprofloxacin               585                        86.1                        66                              17.4                    1   3.8    1    4.5
  Levofloxacin                552                        81.3                        65                              17.1                    1   3.8    0    0.0
  Fosfomycin                  170                        25.0                        35                              9.1                     9   33.3   0    0.0
  Erythromycin                615                        90.6                        235                             61.5                    8   32.0   22   91.7
  Furadantin                  238                        35.0                        10                              2.6                     0   0.0    5    20.0
  Linezolid                   6                          0.9                         4                               1.1                     0   0.0    0    0.0
  Vancomycin                  5                          0.7                         0                               0.0                     0   0.0    0    0.0
  Teicoplanin                 4                          0.6                         0                               0.0                     2   7.1    0    0.0
  Chloramphenicol             65                         9.5                         149                             39.1                    0   0.0    0    0.0
  Quinupristin/dalfopristin   12                         1.8                         310                             81.2                    1   3.8    4    17.4
  Minocycline                 272                        40.0                        200                             52.4                    2   7.1    4    17.4
  Tetracycline                360                        53.0                        277                             72.5                    6   23.1   18   73.9
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###### 

Prevalence of antimicrobial resistance in *Enterococcus* species isolated from different departments of the hospital (%).

  Antibiotics                 Department of burns (*n* = 182), ICU (*n* = 171)   Department of pediatrics (*n* = 164)                        
  --------------------------- -------------------------------------------------- -------------------------------------- ------ ------ ------ ------
  Penicillin                  81.2                                               4.5                                    88.0   11.4   93.6   2.5
  Ampicillin                  77.9                                               2.2                                    89.0   2.7    92.2   0.0
  Gentamicin                  5.5                                                0.0                                    4.3    0.0    1.5    0.0
  Ciprofloxacin               85.8                                               8.9                                    83.2   18.9   77.1   4.7
  Levofloxacin                86.2                                               7.9                                    84.7   17.1   60.5   2.5
  Erythromycin                83.8                                               47.3                                   89.9   59.5   92.9   38.6
  Furadantin                  20.0                                               3.4                                    40.7   2.9    10.0   0.0
  Quinupristin/dalfopristin   1.5                                                77.2                                   0.0    86.5   1.0    66.7
  Tetracycline                62.7                                               67.4                                   50.0   67.6   70.0   69.0

3.5. Effect of Reserpine Treatment on Antimicrobial Sensitivity in Enterococcus Species
---------------------------------------------------------------------------------------

All 100 of the clinical isolates of enterococci grew well on the M-H agar plates with or without reserpine, indicating that reserpine had no inhibitory effects on the growth of *Enterococcus* species. The number of enterococcal isolates resistant to ciprofloxacin, gatifloxacin and levofloxacin was reduced from 42 to 30 following treatment with 20 mg/L reserpine, with a corresponding reduction in the prevalence of resistance from 42% to 30%, while the number of enterococcal isolates resistant to the all three fluoroquinolones was reduced from 30 to 15, with a significant reduction also observed. The MIC alteration of three fluoroquinolones for 100 multiple-drug enterococcal strains before and after reserpine treatment is shown in [Table 7](#ijerph-11-03424-t007){ref-type="table"}. Reduced MIC was observed in 84 clinical isolates of *Enterococcus* species following reserpine treatment, including 72 isolates with increased sensitivity to ciprofloxacin, 55 isolates with increased sensitivity to gatifloxacin and 39 isolates with increased sensitivity to levofloxacin. Following reserpine treatment, 36 isolates had an increased sensitivity to all the three fluoroquinolones, 18 isolated showed an increased sensitivity to two fluoroquinolones, while 30 isolates exhibited an increased sensitivity to a fluoroquinolone ([Table 8](#ijerph-11-03424-t008){ref-type="table"}).

3.6. Prevalence of Antimicrobial Resistance Genes
-------------------------------------------------

Of the 100 multiple-drug resistant enterococcal isolates, there were 38 isolates of *E. faecalis* and 62 isolates of *E. faecium*, while the *TEM*, *aac(6\')/aph(2\'\')*, *aph(3\')-III*, *ant(6)-I*, *ant(2\'\')-I*, *tetM*, *ermB*, *vanA* and *emeA* genes were detected in 77, 62, 26, 13, 36, 31, 66, 5 and 55 multiple-drug resistant enterococcal isolates, respectively. The detection of these antimicrobial resistance genes in 38 isolates of *E. faecalis* and 62 isolates of *E. faecium* is shown in [Table 9](#ijerph-11-03424-t009){ref-type="table"}. The *emeA* gene was detected in 73.8% of the ciprofloxacin-resistant enterococcal isolates, 76.7% of the gatifloxacin-resistant enterococcal isolates, and 75.8% of the levofloxacin-resistant enterococcal isolates, while the prevalence of the *emeA* gene was 41.4%, 45.7% and 44.8% in the ciprofloxacin-, gatifloxacin- and levofloxacin- sensitive enterococcal isolates, respectively ([Table 10](#ijerph-11-03424-t010){ref-type="table"}).
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###### 

Changes in MIC50 and MIC90 of three fluoroquinolones for 100 multiple-drug enterococcal strains before and after reserpine treatment.

  Time                         Ciprofloxacin   Gatifloxacin   Levofloxacin                                
  ---------------------------- --------------- -------------- -------------- ------ ----- ---- ------ --- ----
  Before reserpine treatment   42.0            2              256            30.0   1     32   33.0   2   64
  After reserpine treatment    28.0            0.25           128            17.0   0.5   8    23.0   2   32
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###### 

Changes of antimicrobial sensitivity in 100 enterococcal isolates following treatment with 20 mg/L reserpine.

  Antibiotics     Drug Sensitivity Test   No. Isolates   No. of enterococcal Isolates with Reduced MIC following Treatment with 20 mg/L Reserpine                 
  --------------- ----------------------- -------------- ------------------------------------------------------------------------------------------ ---- --- ---- ---
  Ciprofloxacin   Resistant               42             10                                                                                         6    3   21   2
  Sensitive       58                      4              9                                                                                          19   0   26   
  Gatifloxacin    Resistant               30             7                                                                                          8    1   13   1
  Sensitive       70                      16             4                                                                                          3    3   44   
  Levofloxacin    Resistant               33             11                                                                                         8    5   3    6
  Sensitive       67                      11             1                                                                                          0    0   55   
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###### 

Detection of antibiotic resistance genes in multiple-drug resistant *E. faecalis* and *E. faecium*.

  Antibiotic Resistance Gene   *E. faecalis* Isolate (*n* = 38)   *E. faecium* Isolate (*n* = 62)        
  ---------------------------- ---------------------------------- --------------------------------- ---- ------
  *TEM*                        18                                 47.4                              59   95.1
  *aac(6')/aph(2")*            30                                 78.9                              32   52.4
  *Aph(3')-III*                12                                 31.6                              14   23.3
  *Ant(6)-I*                   4                                  10.5                              9    14.3
  *Ant(2")-I*                  11                                 28.9                              25   39.8
  *tetM*                       12                                 31.6                              19   30.1
  *ermB*                       27                                 71.1                              39   62.1
  *vanA*                       0                                  0.0                               5    8.1
  *emeA*                       10                                 26.3                              45   72.6
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###### 

Prevalence of the *emeA* gene in multiple-drug resistant enterococcal isolates.

  Antibiotics     Antibiotic-resistant enterococcal Isolate   Antibiotic-sensitive enterococcal Isolate   χ^2^    *p*                       
  --------------- ------------------------------------------- ------------------------------------------- ------- ----- ---- ------ ------- ---------
  Ciprofloxacin   42                                          31                                          73.8%   58    24   41.4   13.02   \<0.005
  Gatifloxacin    30                                          23                                          76.7%   70    32   45.7   8.13    \<0.005
  Levofloxacin    33                                          25                                          75.8%   67    30   44.8   8.57    \<0.005

4. Discussion
=============

Due to the spread of enterococcal antimicrobial resistance \[[@B8-ijerph-11-03424],[@B9-ijerph-11-03424]\], the tracing of the infectious sources is of great significance for the control of enterococcal infections and its spreading. Among the 289 enterococcal strainss isolated from a tertiary-care pediatric hospital in Mexico City during an 18-month period, *E. faecalis* and *E. faecium* comprised 81.2% of the total isolates, and antimicrobial resistance in *Enterococcus* spp. was found to be common \[[@B10-ijerph-11-03424]\]. Of the 415 enterococcal isolates obtained from clinical samples between January 1999 and 31 December 2001 in the Mubarak Al-Kabeer, Amiri, Adan, Ibn Sina and Maternity hospitals in Kuwait, *E. faecalis* (85.3%) and *E. faecium* (7.7%) accounted for 93% of the samples \[[@B11-ijerph-11-03424]\]. Salem-Bekhit and colleagues identified 69.2% *E. faecalis* and 11.3% *E. faecium* in 206 enterococcal species obtained from the clinical samples in Riyadh hospitals of King Saud University, Saudi Arabia \[[@B12-ijerph-11-03424]\].

Maschieto *et al.* reported that the distribution of *Enterococcus* spp. isolated from the intestinal tracts of patients from a university hospital in Brazil was *E. faecium* (34%), followed by *E. faecalis* (33%), *E. gallinarum* (23.7%), *E. casseliflavus* (5.2%), *E. avium* (1%), and *E. hirae* (1%) \[[@B13-ijerph-11-03424]\]. In China, *E. faecium* and *E. faecalis* were also found to be predominant in the enterococci isolated from clinical specimens \[[@B14-ijerph-11-03424],[@B15-ijerph-11-03424],[@B16-ijerph-11-03424],[@B17-ijerph-11-03424]\]. Similar to these findings, the current study showed that *E. faecium* (58.7%) and *E. faecalis* (33%) were predominant in the 1157 clinical isolates of *Enterococcus* species isolated from our hospital. However, the present study involved a large sample size, compared the antimicrobial resistance in enterococcal strains isolated from different departments of the hospital, and investigated the efflux mechanism of resistance in enterococci, which is rarely reported previously. The *Enterococcus* species were mainly isolated from the urinary system clinical specimens, which was in agreement with the detection of *Enterococcus* species isolated from the First Affiliated Hospital of Chongqing Medical University \[[@B18-ijerph-11-03424]\]. In addition, *Enterococcus* species were found to be predominantly isolated from the burns department, ICU and pediatrics department, which was associated with the patients' critical illness, long-term antibiotic use and decline in immune function \[[@B19-ijerph-11-03424]\].

*Enterococcus* species are found to be intrinsically resistant to cephalosporins and aminoglycosides. Even though bacteria were found to be sensitive to these drugs in *in-vitro* experiments, unsatisfactory efficacy was found in clinical practice \[[@B2-ijerph-11-03424],[@B20-ijerph-11-03424],[@B21-ijerph-11-03424]\]. Multiple-antimicrobial resistance has been widely reported in *Enterococcus* species \[[@B22-ijerph-11-03424],[@B23-ijerph-11-03424],[@B24-ijerph-11-03424],[@B25-ijerph-11-03424]\].

In the current study, a significantly higher prevalence of resistance to penicillin, ampicillin, rifampicin, ciprofloxacin, levofloxacin, fosfomycin, erythromycin and furadantin was detected in *E. faecium* than in *E. faecalis* (*p* \< 0.05), while a greater prevalence of resistance to chloramphenicol, quinupristin/dalfopristin, minocycline and tetracycline was found in *E. faecalis* than in *E. faecium* (*p* \< 0.05). In addition, a low prevalence of resistance to linezolid, vancomycin and teicoplanin was detected in both *E. faecium* and *E. faecalis*. Therefore, linezolid, vancomycin and teicoplanin are currently widely used drugs for the effective treatment of enterococcal infections \[[@B22-ijerph-11-03424],[@B23-ijerph-11-03424],[@B26-ijerph-11-03424]\]. Quinupristin/dalfopristin, a novel streptogramin antibiotic agent, has been widely used for the treatment of vancomycin-resistant enterococcal infections in USA and Europe, and a high therapeutic efficacy has been achieved \[[@B27-ijerph-11-03424],[@B28-ijerph-11-03424],[@B29-ijerph-11-03424]\]. The mechanism of action of the agent is found to involve early and late stage inhibition of bacterial protein synthesis \[[@B30-ijerph-11-03424],[@B31-ijerph-11-03424]\], however, the drug shows poor efficacy against *E. faecalis* \[[@B32-ijerph-11-03424],[@B33-ijerph-11-03424]\]. High rates of resistance to quinupristin-dalfopristin have been detected in enterococci isolated from poultry production environments \[[@B34-ijerph-11-03424]\], chickens \[[@B35-ijerph-11-03424]\], and clinical specimens \[[@B36-ijerph-11-03424],[@B37-ijerph-11-03424],[@B38-ijerph-11-03424]\]. In the present study, the prevalence of quinupristin-dalfopristin resistance was 81.2% in *E. faecalis*, which was significantly higher than that the 1.8% in *E. faecium* (*p* \< 0.05). In addition, quinupristin/dalfopristin has been recommended by CLSI for the treatment of vancomycin-resistant enterococcal infections. Since antimicrobial resistance varies in *Enterococcus* species, there is a great need to identify enterococcal strains to the species level, which would facilitate the appropriate selection of antibiotics.

Like previous reports \[[@B16-ijerph-11-03424],[@B17-ijerph-11-03424]\], our findings also found that the prevalence of antimicrobial resistance varied in the enterococci isolated from different departments of the hospital. A lower prevalence of antibiotic resistance was detected in the enterococci isolated from the department of pediatrics as compared to those from other departments of the hospital, while a high prevalence of penicillin resistance was found, which may be associated with the frequent application of penicillin, a commonly used drug in pediatrics. A high prevalence of antimicrobial resistance was found in the enterococci isolated from the burns department and ICU of the hospital, which may be attributed to the patients' critical illness, poor immunity and long-term antibiotic use, or the habit of the antibiotic use \[[@B19-ijerph-11-03424]\].

To understand the shift of antimicrobial resistance in enterococci in our hospital, we compared the results from this study to the distribution of antimicrobial resistance in enterococci isolated from clinical specimens during the period from January 2007 through December 2009 \[[@B39-ijerph-11-03424]\], and found a great rise in the number of enterococcal isolates, in which *E. faecium* was still predominant, but its constituent ratio increased. In addition, the enterococcal isolates were still resistant to more than 40% of the commonly used antibiotics; however, no significant rise was found in the prevalence of antimicrobial resistance. In the current study, we identified 10 linezolid-resistant enterococcal strains, which were not detected in the enterococci isolated between 2007 and 2009. It is considered that the continuous antibiotic pressure causes the secondary resistance to linezolid in enterococci \[[@B40-ijerph-11-03424]\].

Reserpine has been proved to reduce the MIC of fluoroquinolones against antimicrobial-resistant bacteria \[[@B41-ijerph-11-03424],[@B42-ijerph-11-03424],[@B43-ijerph-11-03424]\]. It is found that the combination of the multidrug efflux inhibitor reserpine and fluoroquinolone enhances the sensitivity of fluoroquinolone-resistant *Streptococcus pneumonia* and *Staphylococcus aureus* to fluoroquinolones \[[@B44-ijerph-11-03424]\]. Our findings showed that reserpine treatment caused a significant reduction in the resistance to the three fluoroquinolones ciprofloxacin, gatifloxacin and levofloxacin in *Enterococcus* species, and the MIC of fluoroquinolones was reduced by over 2-fold in 72% of the enterococcal isolates.

In the current study, the *emeA* gene was detected in 73.8% of the ciprofloxacin-resistant enterococci, 76.7% of the gatifloxacin-resistant enterococci, and 75.8% of the levofloxacin-resistant enterococci, respectively, suggesting the presence of other mechanisms involved in the resistance of enterococci to the three fluoroquinolones in addition to drug efflux, and such a gene was present in 41.4% of the ciprofloxacin-sensitive enterococci, 45.7% of the gatifloxacin-sensitive enterococci, and 44.8% of the levofloxacin-sensitive enterococci, respectively, indicating no expression of the *emeA* gene in some enterococcal isolates. In addition, the occurrence of the *emeA* gene was significantly greater in the fluoroquinolone-resistant enterococci than that in the fluoroquinolone-sensitive enterococci (*p* \< 0.05), indicating that the distribution of the *emeA* gene was associated with the resistance to the three fluoroquinolones in the *Enterococcus* species.

It is indicated that the resistance of enterococci to β-lactam is caused by the production of β-lactamase, which is encoded by the *TEM* gene, or modification in the penicillin-binding proteins (PBPs) \[[@B45-ijerph-11-03424],[@B46-ijerph-11-03424]\]. In the current study, a high prevalence of penicillin resistance was detected in *E. faecium*, while a low prevalence was found in *E. faecalis*, and the occurrence of the *TEM* gene was 95.1% and 47.4% in *E. faecium* and *E. faecalis*, respectively. The aminoglycosides resistance in enterococci is mainly attributable to the production of aminoglycoside-modifying enzymes \[[@B47-ijerph-11-03424]\]. Currently, over 30 aminoglycoside modifying enzymes have been identified, in which bifunctional 6\'-aminoglycoside acetyltransferase (AAC(6\')) 2\"-aminoglycoside phosphotransferase (APH(2\")) enzyme encoded by the *aac(6\')/aph(2\")* gene is the most common one, which eliminates the synergistic effect between penicillin or glycopeptide antibiotics and aminoglycosides \[[@B48-ijerph-11-03424]\]. Our findings showed that the occurrence of the *aac(6\')/aph(2\")* gene, the *aph(3\')-III* gene that encodes aminoglycoside 3\'-type III phosphotransferase (APH(3\')-III), the *ant(6)-I* gene that encodes 6-nucleotidyltransferase I (ANT(6)-I) and the *ant(2\")-I* gene that encodes aminoglycoside- 2\"-O-nucleotidyltransferase I (ANT(2\")-I) was 62%, 26%, 13% and 36% in the 100 multiple-drug resistant enterococcal isolates, respectively. The resistance of enterococci to tetracyclines is mainly caused by the binding of the *tetM* gene-encoded ribosomal protection proteins to the ribosome, thereby avoiding the effect of tetracyclines \[[@B49-ijerph-11-03424]\]. In the current study, the prevalence of tetracycline resistance gene was 31.6% and 30.1% in *E. faecalis* and *E. faecium*, respectively. It is therefore considered that the resistance of *Enterococcus* species to β-lactam, aminoglycosides and tetracyclines is attributable to the presence of the gene that encodes the corresponding enzymes. Two mechanisms are considered to be responsible for macrolides resistance in enterococci, including the change in the target site of erythromycin mediated by the *erm* gene, and *mef* gene-mediated antimicrobial efflux \[[@B50-ijerph-11-03424],[@B51-ijerph-11-03424]\]. *ermB* gene is the predominant type of erm gene in enterococci \[[@B50-ijerph-11-03424]\]. Our findings showed that the occurrence of the *ermB* gene was 71.1% and 62.1% in *E. faecalis* and *E. faecium*, respectively, indicating that the macrolides resistance in the *Enterococcus* species isolated from Ningxia region is mainly associated with the presence of the *ermB* gene. Like previous studies \[[@B52-ijerph-11-03424],[@B53-ijerph-11-03424]\], the *mefA* gene was detected in enterococci in the current study; however, Liang *et al.* \[[@B54-ijerph-11-03424]\] detected the *mefA* gene in 9 of 53 clinical isolates of *Enterococcus* species, which may be due to the regional variation in the occurrence of the *mefA* gene in enterococci.

It is indicated that the resistance to glycopeptides in enterococci is mainly caused by the alteration of peptidoglycan precursors on the cell wall of enterococci, which leads to the failure of the glycopeptides to inhibiting the synthesis of the cell walls of enterococci, thereby resulting in the emergence of glycopeptide resistance \[[@B55-ijerph-11-03424],[@B56-ijerph-11-03424]\]. In the present study, the *vanA* gene was detected in all of the 5 vancomycin-resistant isolates of enterococci. Vancomycin-resistant enterococci may transfer the *vanA* gene to *S. aureus*, which leads to the emergence of vancomycin-resistant *S. aureus*, thereby resulting in more difficulty in the clinical treatment of enterococcal infections \[[@B5-ijerph-11-03424]\]. Therefore, vancomycin should be used cautiously in the clinical therapy of enterococcal infections, and the management of vancomycin-resistant enterococci should be improved \[[@B22-ijerph-11-03424],[@B57-ijerph-11-03424]\].

5. Conclusions
==============

In summary, enterococci have become the major pathogenic bacteria that cause hospital-acquired infections due to multiple-antimicrobial resistance, and the clinical enterococcal infections predominantly occur in the urinary system. Antimicrobial sensitivity varies in different *Enterococcus* species, and the resistance of enterococci to antimicrobial agents is mainly attributable to the emergence of antimicrobial resistance genes. Reserpine, as an active efflux inhibitor, inhibits the active efflux of *Enterococcus* species, and reduces the MIC of antimicrobial-resistant *Enterococcus* species. The occurrence of the enterococcal multidrug resistance efflux emeA gene is associated with the resistance of enterococci to antimicrobial agents. The monitoring of the prevalence and antimicrobial resistance of *Enterococcus* species would provide a guide for the appropriate selection of antibiotics and prevent the occurrence of more antimicrobial-resistant enterococcal isolates.
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